Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MRKRthis companyMarker Therapeutics, Inc.	$1.01	-1.89×	1.36×	0×	-0.54×	20.2%	0.0%	0.0%	0.0%	-72.4%	-76.6%	-52.7%	0×	1.29×	0×	8.39×	0.0%	2	-41.72	2	C
AEONAEON Biopharma, Inc.	$0.18	-0.28×	-0.2×	0×	-2.69×	-1320.4%	0.0%	0.0%	0.0%	71.3%	1180.0%	-158.6%	-0.65×	-2.02×	0×	0.49×	0.0%	2	-129.27	2	C
BOLTBolt Biotherapeutics, Inc.	$6.22	-0.31×	0.39×	1.33×	-0.67×	-1476.7%	80.6%	-450.1%	-433.7%	-125.9%	-67.7%	-390.3%	0.87×	-0.35×	0×	3.59×	0.0%	2	-18.11	2	C
CLRBCellectar Biosciences, Inc.	$1.31	-0.35×	0.78×	0×	0.24×	259.5%	0.0%	0.0%	0.0%	-219.7%	-222.5%	-300.5%	0.04×	0.59×	0×	2.96×	0.0%	2	-10.78	3	B
COCPCocrystal Pharma, Inc.	$1.08	-1.26×	1.75×	0×	-0.65×	-55.3%	0.0%	0.0%	0.0%	-139.5%	-115.1%	-74.2%	0.24×	0.65×	0×	3.68×	0.0%	3	-108.13	1	C-
IMNNImunon, Inc.	$0.86	-0.56×	1.15×	0×	-0.02×	252.7%	0.0%	0.0%	0.0%	-205.3%	-181.5%	-175.3%	0.14×	0.56×	0×	2.32×	0.1%	1	-42.64	2	C+
Peer median	—	-0.35×	0.78×	0×	-0.65×	-55.3%	0.0%	0.0%	0.0%	-139.5%	-115.1%	-175.3%	0.14×	0.56×	0×	2.96×	0.0%	2	-42.64	2	—